COVID-19

PHILADELPHIA — COVID-19 infections in patients who receive tixagevimab/cilgavimab are “infrequent,” and “mild in severity,” according to early data presented at ACR Convergence 2022.

For adults in the U.K., preexisting neuropsychiatric conditions and having a prescription for a related treatment carried a significantly increased risk of severe outcomes from COVID-19 and other severe acute respiratory infections.

I am very happy to see us featuring long COVID again after our initial foray in Healio Rheumatology in February. Joining me in this discussion are several astute colleagues including Aranka Ballering, MSc, Andrew J. Laster, MD, and Jeffrey A. Sparks, MD, MMSc, who provide insightful comments and have raised many of the unanswered questions surrounding this disorder.

Patients living with HIV prefer in-person visits with physicians to telehealth visits, according to research presented at IDWeek.

SARS-CoV-2-related neurologic effects endured among children and adolescents in the United States who were hospitalized in 2021 for COVID-19 or multisystem inflammatory syndrome, researchers reported in JAMA Neurology.

The FDA’s Pulmonary-Allergy Drug Advisory Committee voted 8-5, leaning against granting sabizabulin emergency use authorization to treat patients hospitalized with COVID-19 and at risk for acute respiratory distress syndrome.

Boston-area school districts that lifted mask mandates earlier this year experienced nearly 45 more cases of COVID-19 per 1,000 students and staff than school districts that kept their mandates in place, a study found.

The FDA has issued an emergency use authorization for anakinra injection in the treatment of COVID-19 among hospitalized adults with pneumonia requiring supplemental oxygen.

Social determinants of health, including lower socioeconomic status and a higher proportion of racially minoritized groups, correlated with higher likelihood of COVID-19-related death, according to a recent study in Clinical Infectious Diseases.

Respiratory tract and total body burden of SARS-CoV-2 infection could predict how long patients will take to recover and provide insight into long COVID, according to a recent study published in Clinical Infectious Diseases.